During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This signals a continued strong interest in the field. AbbVie made a multi-billion dollar acquisition of ImmunoGen, Merck entered into a development agreement with Daiichi, and Pfizer acquired Seagen for a record amount. Evy Lundgren-Åkerlund, CEO of ADC developer Targinta, shares her analysis.
